Access Pressure Still Needs Controls

Access Pressure Still Needs Controls

Urgency has a way of making weak systems sound reasonable.

The product is needed.
The supply is tight.
The normal path is not enough.
The patient population is vulnerable.
The clock is moving.

All true.

But none of that makes control optional.

If anything, pressure makes control more important.

What FDA Said

On September 4, 2026, FDA announced steps to help maintain access to certain starter parenteral nutrition drug products for neonates.

FDA said it became aware of a potential supply gap after children's hospitals raised concerns about continued access. Those concerns were based on the discontinuation of certain standardized neonatal starter parenteral nutrition products made by two outsourcing facilities that are permanently shutting down.

FDA also issued an immediately-in-effect final guidance titled “Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates.”

The guidance describes FDA's temporary regulatory and enforcement priorities for certain compounded starter parenteral nutrition drug products for neonates. FDA says the policies are intended to provide temporary flexibility for 180 days after publication, until March 8, 2027, while alternative sources increase supplies.

FDA also states a basic fact that should not get lost in the access discussion: compounded drug products are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before they reach patients.

Those are the source facts.

Here is the operator lesson:

Temporary flexibility still needs a control strategy.

Access Pressure Is Real

It is easy to talk about quality from a calm conference room.

It is harder when hospitals are worried about access for premature and critically ill newborns.

Starter parenteral nutrition is not a convenience product. FDA describes it as early nutrition for newborns who cannot receive nutrition by mouth or feeding tube while custom, patient-specific formulas are prepared.

That matters.

The access problem is real.

So is the quality risk.

Good operators hold both truths at the same time.

They do not pretend the supply problem is minor.

They also do not pretend that urgency turns a temporary workaround into a controlled process by itself.

Flexibility Is Not the Same as Drift

Regulatory flexibility can be necessary.

But flexibility is not drift.

Drift is what happens when a team says, “We will handle it manually,” and never defines who owns the manual process.

Drift is what happens when a temporary path gets built with tribal knowledge, email threads, and a spreadsheet named something like “FINAL_final_v7.”

Drift is what happens when access pressure becomes the reason nobody wants to ask the hard quality questions out loud.

That is not control.

That is hope wearing a badge.

The Temporary Path Needs Named Controls

FDA's guidance lays out defined circumstances for the temporary policy.

That is the point.

Even temporary flexibility comes with boundaries.

For operators, the practical work is making those boundaries visible inside the actual workflow.

Who is allowed to compound?

Which formulations are in scope?

What beyond-use dating applies?

What storage and handling conditions are required?

What records identify the supplier and the patients who received the product?

What adverse event or quality issue reporting path is active?

What happens when the temporary policy expires?

What is the escalation path if supply demand, batch size, stability data, sterility testing, container-closure integrity, or distribution assumptions change?

None of those questions are theoretical.

They are the difference between a controlled temporary process and a workaround that got lucky.

Records Matter More During a Workaround

When a normal system is stressed, documentation usually gets treated as the thing slowing everyone down.

That is backwards.

Records are how the team keeps control while the process is under pressure.

If multiple pharmacies, hospitals, outsourcing facilities, supply-chain contacts, and quality leaders are involved, memory is not enough.

You need records that show:

Who supplied the product.

Which product and formulation was used.

What dating was assigned.

How it was stored.

Where it went.

Which patients received it.

What quality signals came back.

Who reviewed the signal.

What changed because of it.

That is not paperwork for paperwork's sake.

That is how the organization avoids flying blind.

Quality Ownership Cannot Be Temporary

The policy may be temporary.

The accountability is not.

That is the leadership piece.

When the organization shifts into a temporary supply path, someone has to own the control strategy end to end.

Not “pharmacy has it.”
Not “quality is aware.”
Not “regulatory reviewed the guidance.”
Not “supply chain is tracking it.”

Those may all be true.

They are not enough.

There has to be a working operating model:

Decision rights.
Escalation triggers.
Release expectations.
Traceability.
Complaint and adverse event flow.
Supplier oversight.
Expiration and BUD discipline.
A stop condition.
A transition plan back to a more durable supply path.

That is the work.

The Test Is Not Whether the Team Cares

Most teams care.

That is not the issue.

The issue is whether the system is clear enough to perform when the situation is uncomfortable.

Can the team make access decisions without losing control?

Can they move fast without turning every exception into precedent?

Can they keep records while the phones are ringing?

Can they protect patients without pretending the risk disappeared because the need is urgent?

That is where quality culture becomes operational.

Not aspirational.

Operational.

Pressure Does Not Remove the Job

FDA's neonatal starter PN guidance is a useful reminder because it does not fit neatly into the usual compliance lecture.

This is not a simple “bad company did bad thing” story.

It is a real access problem involving vulnerable patients, temporary policy, compounded products, and supply transition.

That is exactly why the quality lesson matters.

When pressure rises, control cannot become less explicit.

It has to become clearer.

Temporary flexibility should come with temporary guardrails, named ownership, visible records, and a plan for what happens next.

Access matters.

So does control.

In pharma, the hard days usually require both.

Website Publishing Notes

• Stage as Squarespace draft, not published.
• Author must be set to Two Pharma Guys.
• Add SEO title, meta description, URL slug, excerpt, source URL, and image alt text.
• Use the finished hero image at `outputs/access-pressure-still-needs-controls-hero.png`.
• Confirm the draft appears in Blog Content before considering staging complete.